KRAS mutations represent one of the most common oncogenic drivers in LUAD, pancreatic adenocarcinoma, and other malignancies, yet therapeutic options directly targeting KRAS remain limited and prone to resistance. The gene discussed is KRAS; the disease is pancreatic adenocarcinoma.